Rajesh T Gandhi1, Karen T Tashima2, Laura M Smeaton3, Vincent Vu3, Justin Ritz3, Adriana Andrade4, Joseph J Eron5, Evelyn Hogg6, Carl J Fichtenbaum7. 1. Massachusetts General Hospital, Boston. 2. Miriam Hospital, Alpert Medical School of Brown University, Providence, Rhode Island. 3. Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. Division of AIDS, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 5. University of North Carolina at Chapel Hill, Maryland. 6. Social and Scientific Systems, Inc., Silver Spring, Maryland. 7. University of Cincinnati College of Medicine, Ohio.
Abstract
BACKGROUND: Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain. METHODS: Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an optimized regimen including NRTIs. RESULTS: At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96. CONCLUSIONS: HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression. CLINICAL TRIALS REGISTRATION: NCT00537394.
BACKGROUND: Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain. METHODS: Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an optimized regimen including NRTIs. RESULTS: At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96. CONCLUSIONS: HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression. CLINICAL TRIALS REGISTRATION: NCT00537394.
Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Amanda Mocroft; Ole Kirk; Peter Reiss; Stephane De Wit; Dalibor Sedlacek; Marek Beniowski; Jose Gatell; Andrew N Phillips; Bruno Ledergerber; Jens D Lundgren Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min Journal: Lancet Date: 2013-07-03 Impact factor: 79.321
Authors: Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer Journal: N Engl J Med Date: 2008-10-02 Impact factor: 91.245
Authors: Joseph J Eron; David A Cooper; Roy T Steigbigel; Bonaventura Clotet; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey L Lennox; Kim M Strohmaier; Hong Wan; Richard J O Barnard; Bach-Yen T Nguyen; Hedy Teppler Journal: Lancet Infect Dis Date: 2013-05-07 Impact factor: 25.071
Authors: Nicholas I Paton; Cissy Kityo; Jennifer Thompson; Immaculate Nankya; Leonard Bagenda; Anne Hoppe; James Hakim; Andrew Kambugu; Joep J van Oosterhout; Mary Kiconco; Silvia Bertagnolio; Philippa J Easterbrook; Peter Mugyenyi; A Sarah Walker Journal: Lancet HIV Date: 2017-05-08 Impact factor: 12.767
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632